PlexusDx's Precision Peptide Genetic Test can identify genetic factors affecting your response
Several studies have reported an inverse relationship between BMI and therapeutic efficacy, indicating that obesity may attenuate clinical responses to biologic disease modifying anti-rheumatic drugs (bDMARDs)
The Bottom Line Retatrutide is not available in Australia through any legal, regulated channel
What's New: July 2026 Update TRIUMPH-4 confirmed: 28.7% weight loss at 68 weeks in 445 participants topline results announced December 2025 TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients the pivotal general obesity trial met all primary and key secondary endpoints TRIUMPH-1 extension: In a prespecified 104-week extension, patients with BMI 35 reached 30.3% average weight loss no plateau observed TRANSCEND-T2D-1 confirmed (topline March 2026, published June 2026): First dedicated Phase 3 diabetes trial -2.0% HbA1c and 16.8% weight loss in 537 type 2 diabetes patients OSA data confirmed (ADA June 6, 2026): TRIUMPH-1's nested sleep apnea substudy showed 60.6% AHI reduction from a severe-OSA baseline of 58.6 events/hour TRIUMPH-2 (obesity + diabetes) and TRIUMPH-3 (obesity + cardiovascular disease) results expected later in 2026 Efficacy Summary Across All Completed Trials Phase 2: The Foundation (2023) The Phase 2 trial, published in the New England Journal of Medicine in June 2023, evaluated retatrutide in 338 adults with obesity (BMI 30) or overweight (BMI 27) with weight-related comorbidities
GLP1(936) inhibits glucagon secretion through a GCGRdependent mechanism by activating inhibitory G proteins (Gi/o) and suppressing PKA activity
Smriti Choudhary, MD , along with their staff , are here to give you the best care possible
